Patents by Inventor Daniel C. Maneval
Daniel C. Maneval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190083449Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.Type: ApplicationFiled: October 18, 2018Publication date: March 21, 2019Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
-
Patent number: 10137104Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.Type: GrantFiled: June 16, 2017Date of Patent: November 27, 2018Assignee: Halozyme, Inc.Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
-
Patent number: 9913822Abstract: Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.Type: GrantFiled: March 15, 2013Date of Patent: March 13, 2018Assignee: Halozyme, Inc.Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
-
Publication number: 20170290796Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.Type: ApplicationFiled: June 16, 2017Publication date: October 12, 2017Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
-
Publication number: 20130302400Abstract: Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.Type: ApplicationFiled: March 15, 2013Publication date: November 14, 2013Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
-
Publication number: 20110104118Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.Type: ApplicationFiled: October 26, 2010Publication date: May 5, 2011Applicant: Canji, Inc.Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
-
Publication number: 20090088398Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective.Type: ApplicationFiled: May 27, 2008Publication date: April 2, 2009Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20090082289Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention- can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: May 2, 2007Publication date: March 26, 2009Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20090048148Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.Type: ApplicationFiled: March 28, 2008Publication date: February 19, 2009Applicant: Canji, IncInventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
-
Patent number: 7462351Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.Type: GrantFiled: May 25, 2006Date of Patent: December 9, 2008Assignees: Canji, Inc., Innovata LimitedInventors: Susan E. Conroy, Heidrun Engler, Daniel C. Maneval
-
Publication number: 20080299083Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: June 14, 2007Publication date: December 4, 2008Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20080286239Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.Type: ApplicationFiled: May 28, 2008Publication date: November 20, 2008Applicant: Canji, Inc.Inventors: Loretta Nielsen, Jo Ann Horowitz, Daniel C. Maneval, G. William Demers, Mary Ellen Rybak, Gene Resnick
-
Publication number: 20080182807Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: November 20, 2006Publication date: July 31, 2008Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20080175818Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).Type: ApplicationFiled: April 25, 2007Publication date: July 24, 2008Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Patent number: 7157079Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.Type: GrantFiled: April 13, 2004Date of Patent: January 2, 2007Assignee: Canji, Inc.Inventors: Loretta Nielsen, Jo Ann Horowitz, Daniel C. Maneval, G. William Demers
-
Patent number: 7105156Abstract: Disclosed are methods of controlling cell cycle progression by introducing into a cell to be controlled a composition selected from the group consisting of p56RB protein, a fragment of the p56RB protein, and the gene encoding p56RB protein to alter the cell cycle progression while maintaining the viability of the cell. The p56RB protein has been found to have the unexpected and surprising characteristic of being soluble in low concentrations of glycerol, thereby enhancing its value in pharmaceutical applications and the gene encoding p56RB when delivered to the hyperproliferating cell inhibits cellular proliferation.Type: GrantFiled: June 7, 1995Date of Patent: September 12, 2006Assignees: The Regents of the University of California, Canji, Inc.Inventors: Wen-Hwa Lee, H. Michael Shepard, Richard J. Gregory, Ken N. Wills, Daniel C. Maneval, Eva Lee, David Goodrich, Nan-Ping Wang
-
Patent number: 7094583Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.Type: GrantFiled: August 6, 2004Date of Patent: August 22, 2006Assignees: Canji, Inc., Innovata PLCInventors: Susan E. Conroy, Engler Heidrun, Daniel C. Maneval
-
Patent number: 7041284Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine dinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective.Type: GrantFiled: October 28, 1997Date of Patent: May 9, 2006Assignee: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Patent number: 6989268Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with thymidine kinase metabolite in order to be effective).Type: GrantFiled: May 19, 2003Date of Patent: January 24, 2006Assignee: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval
-
Publication number: 20040266006Abstract: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.Type: ApplicationFiled: January 27, 2004Publication date: December 30, 2004Applicant: Canji, Inc.Inventors: Richard J. Gregory, Ken N. Wills, Daniel C. Maneval